
Andrea Lania

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12068791/publications.pdf Version: 2024-02-01



Δηρφέλ Ιλνιλ

#	Article	IF	CITATIONS
1	Thyrotoxicosis in patients with COVID-19: the THYRCOV study. European Journal of Endocrinology, 2020, 183, 381-387.	3.7	262
2	Calciumâ€sensing receptor expression and signalling in human parathyroid adenomas and primary hyperplasia. Clinical Endocrinology, 2000, 52, 339-348.	2.4	94
3	Central hypothyroidism — a neglected thyroid disorder. Nature Reviews Endocrinology, 2017, 13, 588-598.	9.6	92
4	Central hypothyroidism. Pituitary, 2008, 11, 181-186.	2.9	75
5	Constitutively Active Gsα Is Associated with an Increased Phosphodiesterase Activity in Human Growth Hormone-Secreting Adenomas1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 1624-1628.	3.6	71
6	Genetics of Pituitary Tumors: Focus on G-Protein Mutations. Experimental Biology and Medicine, 2003, 228, 1004-1017.	2.4	57
7	Induction of Specific Phosphodiesterase Isoforms by Constitutive Activation of the cAMP Pathway in Autonomous Thyroid Adenomas1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2872-2878.	3.6	56
8	Expression of the Antiapoptotic Gene Seladin-1 and Octreotide-Induced Apoptosis in Growth Hormone-Secreting and Nonfunctioning Pituitary Adenomas. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 6156-6161.	3.6	55
9	The dopamine–somatostatin chimeric compound BIM-23A760 exerts antiproliferative and cytotoxic effects in human non-functioning pituitary tumors by activating ERK1/2 and p38 pathways. Cancer Letters, 2010, 288, 170-176.	7.2	49
10	Activating Mutations of the Gsα Gene Are Associated with Low Levels of Gsα Protein in Growth Hormone-Secreting Tumors1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 4386-4390.	3.6	47
11	G protein abnormalities in pituitary adenomas. Molecular and Cellular Endocrinology, 1998, 142, 1-14.	3.2	40
12	The Third Intracellular Loop of the Human Somatostatin Receptor 5 Is Crucial for Arrestin Binding and Receptor Internalization after Somatostatin Stimulation. Molecular Endocrinology, 2008, 22, 676-688.	3.7	39
13	Pathogenesis of Prolactinomas. Pituitary, 2005, 8, 7-15.	2.9	30
14	Hypothalamic Peptides Modulate Cytosolic Free Ca ²⁺ Levels and Adenylyl Cyclase Activity in Human Nonfunctioning Pituitary Adenomas*. Journal of Clinical Endocrinology and Metabolism, 1991, 73, 913-918.	3.6	29
15	Expression of Calcium-Sensing Receptor and Characterization of Intracellular Signaling in Human Pituitary Adenomas1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2848-2853.	3.6	29
16	Inhibition of Basal and Corticotropin-Releasing Hormone-Stimulated Adenylate Cyclase Activity and Cytosolic Ca ²⁺ Levels by Somatostatin in Human Corticotropin-Secreting Pituitary Adenomas*. Journal of Clinical Endocrinology and Metabolism, 1990, 70, 1262-1268.	3.6	26
17	Hormonal Signaling and Pituitary Adenomas. Neuroendocrinology, 2007, 85, 101-109.	2.5	17
18	G-Protein and Signalling in Pituitary Tumours. Hormone Research in Paediatrics, 2009, 71, 95-100.	1.8	17

2

Andrea Lania

#	Article	IF	CITATIONS
19	Outcome of Sars-COV-2-related thyrotoxicosis in survivors of Covid-19: a prospective study. Endocrine, 2021, 73, 255-260.	2.3	16
20	Skeletal health in patients with differentiated thyroid carcinoma. Journal of Endocrinological Investigation, 2021, 44, 431-442.	3.3	15
21	Pituitary incidentalomas. Best Practice and Research in Clinical Endocrinology and Metabolism, 2012, 26, 395-403.	4.7	12
22	Mechanism of Action of Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) in Human Nonfunctioning Pituitary Tumors. Journal of Neuroendocrinology, 1995, 7, 695-702.	2.6	11
23	Growth factors and human pituitary adenomas. Molecular and Cellular Endocrinology, 2002, 197, 63-68.	3.2	11
24	cAMP pathway and pituitary tumorigenesis. Annales D'Endocrinologie, 2012, 73, 73-75.	1.4	9
25	Cellular abnormalities in pituitary tumors. Metabolism: Clinical and Experimental, 1996, 45, 46-48.	3.4	7
26	Expression of protein kinase A regulatory subunits in benign and malignant human thyroid tissues: A systematic review. Experimental Cell Research, 2016, 346, 85-90.	2.6	7
27	Impact of Thyroid Autoimmunity on Assisted Reproductive Technology Outcomes and Ovarian Reserve Markers: An Updated Systematic Review and Meta-Analysis. Thyroid, 2022, 32, 1010-1028.	4.5	7
28	Levothyroxine supplementation on assisted reproduction technology (ART) outcomes in women with subtle hypothyroidism: a retrospective study. Gynecological Endocrinology, 2018, 34, 1053-1058.	1.7	4
29	Thyrotrophin-Releasing Hormone Raises Cytosolic Free Calcium Concentration in Human Adenomatous Somatotrophs and Corticotrophs; Comparison with in vivo Responsiveness to Thyrotrophin-Releasing Hormone in Patients with Acromegaly or Cushing's Disease. Journal of Neuroendocrinology, 1991, 3, 51-56.	2.6	2
30	Central Hypothyroidism. , 2019, , 245-253.		0
31	Central Hypothyroidism. Endocrinology, 2016, , 1-17.	0.1	0
32	Central Hypothyroidism. Endocrinology, 2018, , 373-389.	0.1	0
33	Molecular Pathogenesis of Pituitary Adenomas. , 2008, , 1-15.		0